Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI in Patients With STEMI.

Trial Profile

Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI in Patients With STEMI.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Oct 2011

At a glance

  • Drugs Exenatide (Primary)
  • Indications Myocardial reperfusion injury
  • Focus Therapeutic Use
  • Acronyms POSTCON-II
  • Most Recent Events

    • 14 Sep 2011 Results published in the European Heart Journal.
    • 22 Dec 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 11 Feb 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top